[go: up one dir, main page]

MA41218A - Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr - Google Patents

Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr

Info

Publication number
MA41218A
MA41218A MA041218A MA41218A MA41218A MA 41218 A MA41218 A MA 41218A MA 041218 A MA041218 A MA 041218A MA 41218 A MA41218 A MA 41218A MA 41218 A MA41218 A MA 41218A
Authority
MA
Morocco
Prior art keywords
vaccine combination
gitr antibodies
listeria vaccine
listeria
gitr
Prior art date
Application number
MA041218A
Other languages
English (en)
Inventor
Samir Khleif
Mikayel Mkrtichyan
Robert Petit
Anu Wallecha
Original Assignee
Advaxis Inc
Univ Res Inst Inc Augusta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc, Univ Res Inst Inc Augusta filed Critical Advaxis Inc
Publication of MA41218A publication Critical patent/MA41218A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA041218A 2014-12-19 2015-12-17 Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr MA41218A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462094472P 2014-12-19 2014-12-19
US201462094349P 2014-12-19 2014-12-19
US201562147463P 2015-04-14 2015-04-14
US201562262896P 2015-12-03 2015-12-03

Publications (1)

Publication Number Publication Date
MA41218A true MA41218A (fr) 2017-10-24

Family

ID=56127737

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041217A MA41217A (fr) 2014-12-19 2015-12-17 Polythérapies ayant des souches de listeria recombinées
MA041218A MA41218A (fr) 2014-12-19 2015-12-17 Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA041217A MA41217A (fr) 2014-12-19 2015-12-17 Polythérapies ayant des souches de listeria recombinées

Country Status (14)

Country Link
US (2) US20170368157A1 (fr)
EP (2) EP3234106A4 (fr)
JP (2) JP2018501244A (fr)
KR (2) KR20170096012A (fr)
CN (2) CN107427565A (fr)
AU (2) AU2015364260A1 (fr)
CA (2) CA2971220A1 (fr)
HK (2) HK1246341A1 (fr)
IL (2) IL252680A0 (fr)
MA (2) MA41217A (fr)
MX (2) MX2017008173A (fr)
SG (2) SG11201704599PA (fr)
TW (2) TW201636360A (fr)
WO (2) WO2016100929A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (fr) 2011-03-11 2012-09-20 Advaxis Adjuvants à base de listeria
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
BR112016019057A2 (pt) 2014-02-18 2017-10-10 Advaxis Inc método de induzir uma resposta imune contra uma doença em um indivíduo
WO2015164121A1 (fr) 2014-04-24 2015-10-29 Advaxis, Inc. Souches de listeria utilisées comme vaccin recombinant et procédé de production
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016183361A1 (fr) * 2015-05-13 2016-11-17 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des protéines hybrides d'acta tronqué-antigène et procédés d'utilisation de ces compositions
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
MA49863A (fr) 2016-11-01 2020-06-17 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
MA46721A (fr) * 2016-11-07 2019-09-11 Advaxis Inc Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
CA3035591A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
PL3565844T3 (pl) 2017-01-09 2023-06-12 Tesaro Inc. Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN109136275B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
WO2019060115A1 (fr) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions et procédés de lyophilisation de bactéries ou de souches de listeria
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
SG11202008820WA (en) * 2018-03-09 2020-10-29 Advaxis Inc Compositions and methods for evaluating attenuation and infectivity of listeria strains
CN120943884A (zh) 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
CN110579608B (zh) * 2018-06-11 2022-07-08 苏州若泰医药科技有限公司 一种筛选高表达外源蛋白的非整合减毒李斯特菌菌株的方法
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
EP4004052A4 (fr) * 2019-07-30 2023-11-01 Provention Bio, Inc. Procédés et compositions permettant de réduire l'immunogénicité par des inhibiteurs de lymphocytes b non appauvris
WO2021098750A1 (fr) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Procédés de traitement du cancer avec un anticorps anti-ox40 en combinaison avec des agonistes de tlr
US20240093318A1 (en) 2020-06-23 2024-03-21 The Regents Of The University Of Colorado, A Body Corporate Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes
EP4225770A1 (fr) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Procédés pour concentrer des protéines
EP4490166A1 (fr) 2022-03-09 2025-01-15 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques
CN114736295B (zh) * 2022-06-14 2022-08-09 北京科跃中楷生物技术有限公司 一种辣根过氧化物酶标记抗体及其制备方法
WO2024258913A1 (fr) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Traitement de tumeurs solides avec un régime de thérapie par radionucléides ciblée et de thérapies à base de cellules immunitaires génétiquement modifiées

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255196A1 (en) * 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US10106619B2 (en) * 2006-10-04 2018-10-23 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with OX40 agonist compositions
EP1921149A1 (fr) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganimses portant des séquences nucléotidiques codant pour des antigènes et des toxines, procédé de fabrication, et leurs utilisations
CN101214372A (zh) * 2008-01-04 2008-07-09 中国人民解放军第四军医大学 一种体内诱导出针对TNF-α分子的自身抗体的蛋白疫苗的构建方法
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
WO2014047350A1 (fr) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Virus oncolytique codant pour des agents de liaison de pd-1 et ses utilisations
US20140356930A1 (en) * 2013-06-03 2014-12-04 Panacea Pharmaceuticals Immune system enhancing immunotherapy for the treatment of cancer

Also Published As

Publication number Publication date
HK1245331A1 (zh) 2018-08-24
MX2017008173A (es) 2017-09-18
US20180153974A1 (en) 2018-06-07
SG11201704599PA (en) 2017-07-28
KR20170092626A (ko) 2017-08-11
EP3234148A1 (fr) 2017-10-25
IL252680A0 (en) 2017-08-31
HK1246341A1 (zh) 2018-09-07
WO2016100924A1 (fr) 2016-06-23
IL252743A0 (en) 2017-08-31
KR20170096012A (ko) 2017-08-23
SG11201704662SA (en) 2017-07-28
CN107427565A (zh) 2017-12-01
MA41217A (fr) 2017-10-24
TW201639594A (zh) 2016-11-16
US20170368157A1 (en) 2017-12-28
JP2018501244A (ja) 2018-01-18
CA2971220A1 (fr) 2016-06-23
MX2017008187A (es) 2017-09-13
JP2018501243A (ja) 2018-01-18
AU2015364260A1 (en) 2017-07-20
EP3234106A4 (fr) 2018-07-18
WO2016100929A1 (fr) 2016-06-23
EP3234106A1 (fr) 2017-10-25
TW201636360A (zh) 2016-10-16
CN107206060A (zh) 2017-09-26
CA2971455A1 (fr) 2016-06-23
AU2015364255A1 (en) 2017-07-20
EP3234148A4 (fr) 2018-10-17

Similar Documents

Publication Publication Date Title
MA41218A (fr) Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA46766A (fr) Vaccin antigrippal
EP3473270A4 (fr) Conjugué anticorps-médicament
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3334824A4 (fr) Anticorps anti-pd-1
EP3334757A4 (fr) Anticorps anti-tigit
MA46272A (fr) Anticorps anti-cd27
MA47472A (fr) Anticorps
DK3518862T3 (da) Medicinindretning
EP3297671A4 (fr) Anticorps anti-ror1
MA53297A (fr) Anticorps anti-icos
DK3302649T3 (da) Lægemiddeladministrationsanordning med lydindikatorfjeder
HUE045866T2 (hu) CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához
LT3569216T (lt) Vieno ar kelių medicininių konteinerių surinkimo įtaisas
PT3311171T (pt) Epítopo de anticorpos
DK3199161T3 (da) Farmaceutisk præparat
EP3389591C0 (fr) Dispositif d&#39;administration médicale
MA51554A (fr) Anticorps il-6 améliorés
MA42843A (fr) Anticorps anti-cd115
EP3336185A4 (fr) Anticorps
DK3115019T3 (da) Fastgørelsesindretning til tandprotesefiksering
EP3246047C0 (fr) Médicament d&#39;association
EP3560512A4 (fr) Composition de vaccin contre le zona
EP3435910C0 (fr) Dispositif de localisation de canule